Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710

April 10, 2011 11:33 pm | by Bio-Medicine.Org | News | Comments

WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 /- Merck (NYSE: MRK ), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an...

Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema

April 7, 2011 11:34 pm | by Bio-Medicine.Org | News | Comments

TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Bayer HealthCare today announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an...

Study Highlights Successes of Ascension Health Quality Initiative

April 7, 2011 8:38 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, April 7, 2011 /- A study published in the journal Health Affairs documents Ascension Health, the nation's third-largest health system, has achieved remarkable results in eliminating preventable mortality, lowering birth trauma rates, reducing bed sores and keeping patients...


NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction

April 7, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

SANTA CLARA, Calif., April 7, 2011 /- PR Newswire – NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that the Company has been invited by the American Diabetes Association (ADA) to present the results of a key study showing that NewCardio's...

Cellular Dynamics Raises $30 Million to Expand Its Product Line of Human Stem Cells and Tissue Cells

April 7, 2011 2:34 am | by Bio-Medicine.Org | News | Comments

MADISON, Wis., April 7, 2011 /- Cellular Dynamics International, Inc. (CDI), the world's only industrial manufacturer of human induced pluripotent stem cells (iPSCs) and tissue cells, has closed on a $30 million private equity round. This recent Series B Preferred Stock financing was led...

Bloxx Provides Peterborough & Stamford Hospitals NHS Foundation Trust with Cost-Effective and Superior Web Filtering

April 6, 2011 1:34 am | by RealWire | News | Comments

Increased levels of user and network protection with lower total cost of ownership, simplified on-going management and reduced risk and liability delivered by real-time Web filteringBloxx, the innovator in Web and Email content filtering, today announced that Peterborough & Stamford...

Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature

April 5, 2011 10:34 pm | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO and ILLKIRCH, France, April 6, 2011 /- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a...

New Study Results Presented on Dexlansoprazole and Lansoprazole Effects on Plavix® (clopidogrel bisulfate)

April 5, 2011 10:34 am | by Bio-Medicine.Org | News | Comments

NEW ORLEANS, April 5, 2011 /- Takeda Pharmaceuticals North America, Inc. (Takeda) announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in...


NeuroVasx Receives FDA Approval for cPAX Aneurysm Treatment System

April 5, 2011 10:34 am | by Bio-Medicine.Org | News | Comments

MAPLE GROVE, Minn., April 5, 2011 /- NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device (HDE) for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat.  The HDE...

Penn Study Sheds Light on End of Life Management of Implanted Defibrillators

April 5, 2011 7:35 am | by University Of Pennsylvania | News | Comments

Each year, more than 100,000 patients in the U.S. undergo implantation of a new implantable cardioverter defibrillator (ICD) for heart rhythm abnormalities. This number constitutes a 20-fold increase over the last 15 years. Current medical guidelines advocate discussion of end of life...

Boston Scientific Begins International Clinical Trial Enrollment for INNOVAâ„¢ Self-Expanding Bare-Metal Stent System

April 5, 2011 4:34 am | by Boston Scientific | News | Comments

Innovative stent designed to treat peripheral vascular lesions for stenoses in arteries above the knee

Covidien Announces Interim Data Showing Single Incision Gall Bladder Surgery with SILS(TM) Port Associated with Improved Cosmetic Outcome Compared to Four-Port Laparoscopic Ap...

April 5, 2011 3:34 am | by Covidien | News | Comments

Interim results of a 10-site prospective clinical study presented at SAGES 2011 NORTH HAVEN, Conn., Apr 05, 2011 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced interim results of its multicenter, international, prospective...

BridgeHead Software Wins Storage Management Contract with The London Clinic

April 5, 2011 2:33 am | by RealWire | News | Comments

First Step to The London Clinic's New IT Infrastructure: Improve Data Availability and Speed up Disaster Recovery TimesHC2011, The ICC Birmingham, 5th April 2011 - BridgeHead Software, a leader in healthcare data and storage management, has won a contract to provide data backup and...


Volcano Announces the Introduction of the PrimeWire PRESTIGE® Pressure Guide Wire in Japan

April 5, 2011 12:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, April 5, 2011 /- Volcano Corporation (NASDAQ: VOLC ) today announced it has received clearance to market the PrimeWire PRESTIGE® pressure guide wire in Japan. In addition to accurately measuring intravascular pressure via Fractional Flow Reserve (FFR), the PrimeWire...

Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session

April 4, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

NEW ORLEANS and CHAPEL HILL, N.C., April 4, 2011 /- Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's (ACC) 60th Annual Scientific Session & Expo in New...

Boston Scientific's Promus Elementâ„¢ Platinum Chromium Stent System Demonstrates Comparable Safety And Effectiveness Outcomes Versus Leading Drug-Eluting Stent In Platinum Work...

April 4, 2011 9:33 am | by Boston Scientific | News | Comments

Reduction of geographic miss and bail-out stenting observed with highly visible PROMUS Element Stent

Severe Psoriasis Linked to Major Adverse Cardiovascular Events

April 4, 2011 8:39 am | by University Of Pennsylvania | News | Comments

Psoriasis is a common inflammatory skin disease, and if severe, has been demonstrated to be a risk factor for cardiovascular (CV) disease. However, the degree to which psoriasis is associated with major adverse cardiac events (MACE), such as heart attack, stroke, and cardiovascular death...

Parent Project Muscular Dystrophy Awards $750,000 Grant to Sildenafil/Taladafil Study

April 4, 2011 8:39 am | by Bio-Medicine.Org | News | Comments

HACKENSACK, N.J., April 4, 2011 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) – the largest, most comprehensive  non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne) – announced today that...

Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology

April 4, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

CULVER CITY, Calif., April 4, 2011 /- Sofie Biosciences, a developer of molecular imaging systems and agents, announced the launch of GENISYS4, their new benchtop small animal PET system. Introduced today at the 2011 American Association for Cancer Research Annual Meeting, this compact,...

Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits

April 4, 2011 3:32 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., April 4, 2011 /- VIVUS, Inc. (Nasdaq: VVUS ) today announced long-term data that demonstrated patients treated with the investigational drug QNEXA® for two years showed reductions in blood pressure and the use of antihypertensive medications as well as...

Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System

April 3, 2011 12:34 pm | by Bio-Medicine.Org | News | Comments

BASKING RIDGE, N.J., April 3, 2011 /- Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the...

Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®

April 3, 2011 7:34 am | by Bio-Medicine.Org | News | Comments

NEW ORLEANS, April 3, 2011 /- A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's (NYSE: ABT ) market-leading XIENCE V ® Everolimus Eluting Coronary Stent System. As part of the analysis of...

Boston Scientific IONâ„¢ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data

April 3, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

NATICK, Mass. and NEW ORLEANS, April 3, 2011 /- Boston Scientific Corporation (NYSE: BSX ) today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the...

REMEDIAL II Results on PLC System's RenalGuard® to be Presented at ACC 2011's Late Breaking Clinical Trial Session

April 1, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

FRANKLIN, Mass., April 1, 2011 /- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today reported that final results from the REMEDIAL II investigator-sponsored clinical trial of its RenalGuard System™ in Italy are scheduled to be...

Haemonetics Sets Date for Fourth Quarter Fiscal Year 2011 Earnings Release: May 2, 2011

April 1, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

BRAINTREE, Mass., April 1, 2011 /- Haemonetics Corporation (NYSE: HAE ) will announce its earnings for the fourth quarter and full year of its 2011 fiscal year and provide full year guidance for fiscal 2012, on May 2, 2011 in a pre-market press release.  The Company will hold a...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.